* Therapeutic indications:
& & – Active management of the third stage of labor (as means to promote separation of the
& & placenta and to reduce blood loss).
& & – Treatment of Uterine atony/haemorrhage occuring during and after the third stage of labor,
& & in association with Cesarean section or following abortion.
& & – Treatment of subinvolution of the uterus, lochiometra, puerperal bleeding. Methergin is not
& & recommended during breast-feeding.
* Posology and Method of Administration:
& & – Active management of the third stage of labor:
& & 0.5 to 1 mL (0.1 to 0.2 mg) slowly I.V. following delivery of the anterior shoulder or, at the latest,
& & immediately after delivery of the child. Explusion of the placenta, usually separated by the first
& & strong contraction following Methergin, should be manually assisted by applying fundal pressure.
& & For delivery under general anesthesia, the recommended dose is 1 mL (0.2 mg).
& & – Treatment of Uterine Atony/hemorrhage:
& & 1 mL (0.2 mg) I.M. or 0.5 to 1 mL (0.1 to 0.2 mg) slowly I.V. May be repeated every 2 to 4 hours,
& & if necessary, up to 5 doses within 24 hours.
& & – Treatment of Subinovulation, Lochiometra Bleeding:
& & 0.125 to 0.25 md p.o. (1 or 2 tablets or 0.5 to 1 mL (0.1 ot 0.2 mg) S.C. or I.M. up to 3 times daily.
& & – Pregnancy; first stage of labor; second stage of labor before crowning of the head (Methergin
& & must not be used for induction or enhancement of labor);
& & – Severe hypertension;
& & – Pre-eclampsia and eclampsia occlusive vascular disease (incl. ischemic heart disease);
& & – Sepsis;
& & – Known hypersensitivity to ergot alkaloids or to any other component of the formulation.
& & – In breech presentations Methergin should not be given before delivery of the child is completed, and
& & in multiple births not before the last child has been delivered.
& & – Active management of the third stage of labor requires obstetric supervision.
& & – Intravenous injections should be given slowly over a period of not less than 60 seconds with
& & careful monitoring of blood pressure.
& & – Intra-or periarterial injection must be avoided.
& & – Caution should be exercised in the presence of mild or moderate hypertension (severe hypertension
& & is a contraindication) or impaired hepatic or renal function.
* Use during pregnancy and lactation:
& & – The use of Methergin in pregnancy is contraindicated because of its potent uterotonic activity.
& & – Methergin has been reported to reduce milk secretion and to be excreted in the breast milk.
& & There have been isolated reported of intoxication in breast-fed infants whose mothers were
& & receiving the drug for several days. One or more of the symptoms were observed (and disappeared
& & upon withdrawal of the medication): elevated blood pressure, bradycardia or tachycardia,
& & vomiting, diarrhea, restlessness, clonic cramps. In view of the possible side effects of the child
& & and the reduction of the milk yield Methergin is not recommended for use during breast-feeding.
* Effects on ability to drive and use machines:
& & – None known. However, caution should be exercised when driving or operating machines,
& & especially at the start of treatment.
* Code: 6223002640966
* Therapeutic indications:
METHYLERGOMETRINE HYDROGEN MALEATE 0.125 MG - indicated for: active management of the third stage of labor, treatment of Uterine Atony/hemorrhage && treatment of Subinovulation, Lochiometra Bleeding - Dose: 1-2 tablets, 3 times daily